Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Purchases of Investments
Cash used to buy marketable securities and other investments.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments declines year over year
Q1 FY2026 purchases of investments of $6.44M (cash outflow) fell 65.2% year over year, ahead of the -82.6% change in trailing-twelve-month purchases of investments. Sequentially, it fell 14.6% from the prior quarter.
Context
- Purchases of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -65.2% holds above the trailing-twelve-month pace of -82.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (44.88M) USD
- Year-over-year change
- +74.5%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (44.88M) | +74.5% |
| FY2024 | 2024-12-31 | (176.17M) | -255.8% |
| FY2023 | 2023-12-31 | (49.52M) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Purchases of Investments vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -82.6% is the lowest of 7, against a peer median of +27.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $247.27M USD | -47.3% | +6.9% | 248.2% | |
| LTM Mar 2026 | $160.3M USD | +74.4% | -48.5% | — | |
| LTM Mar 2026 | $149.91M USD | +9.1% | -36.0% | — | |
| LTM Mar 2026 | €46.43M EUR | +46.1% | -11.8% | 158301.3% | |
| LTM Mar 2026 | $43.48M USD | -21.3% | -31.0% | 4348.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $32.8M USD | -82.6% | — | — |
| FY2025 | $30.47M USD | +97.2% | -35.5% | 47609.4% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ARTV) | — | +27.6% | -33.3% | 4348.3% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.83M) | (58.79M) | (28.72M) | (65.37M) | (83.87M) |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.31M | 6.58M | 7.05M | 6.98M | 6.82M |
| Change in Working Capital | 33.41M | (3.87M) | (28.28M) | (325K) | (424K) |
| Accounts Receivables | (468K) | (57K) | (1.23M) | 1.61M | 79K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.24M) | 190K | (408K) | 519K | (760K) |
| Other Working Capital | 35.13M | (4M) | (26.64M) | (2.46M) | 257K |
| Other Non-Cash Items | 18.55M | 4.08M | 251K | 1.26M | (1.88M) |
| Operating Cash Flow | (15.3M) | (50.83M) | (47.43M) | (55.03M) | (76.75M) |
| Capital Expenditures | (1.72M) | (6.3M) | (3.26M) | (642K) | (2.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (49.52M) | (176.17M) | (44.88M) |
| Sales of Investments | 0 | 0 | 26.8M | 56.35M | 110.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.72M) | (6.3M) | (25.98M) | (120.46M) | 63.41M |
| Debt Repayment | 0 | 0 | 0 | (149K) | (132K) |
| Common Stock Issued | 0 | 0 | 0 | 166.51M | 371K |
| Common Stock Repurchased | 0 | (5K) | (12K) | (4.18M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.86M) | (1.26M) | 24.4M | 51K | (230K) |
| Financing Cash Flow | 152.75M | (1.26M) | 24.39M | 162.23M | 9K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 135.73M | (58.39M) | (49.01M) | (13.27M) | (13.33M) |
| Free Cash Flow | (17.03M) | (57.13M) | (50.69M) | (55.67M) | (79.34M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.